Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Latest Information Update: 03 Oct 2023
At a glance
- Drugs Balstilimab (Primary)
- Indications B-cell lymphoma; Hodgkin's disease
- Focus Therapeutic Use
- 26 Sep 2023 Planned End Date changed from 1 Jun 2029 to 1 Sep 2029.
- 26 Sep 2023 Planned primary completion date changed from 1 Jun 2029 to 1 Sep 2029.
- 26 Sep 2023 Status changed from not yet recruiting to recruiting.